Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction

Published:2024-05-03 Issue:3 Volume:20 Page:1043-1047
ISSN:1734-1922
Container-title:Archives of Medical Science
language:
Short-container-title:Arch Med Sci

Author:

Zimodro Jakub Michal¹^ORCID,Gąsecka Aleksandra¹^ORCID,Arski Piotr¹,Schwarz Jonas²,Banach Maciej³^ORCID,Gouni-Berthold Ioanna²^ORCID

Affiliation:

1. 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

2. Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany

3. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland

Publisher

Termedia Sp. z.o.o.

Link

https://www.archivesofmedicalscience.com/pdf-188252-112123

Reference17 articles.

1. Björnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol 2024; 83: 385-95.

2. Kronenberg F. Lipoprotein(a): from causality to treatment. Curr Atheroscler Rep 2024; 26: 75-82.

3. Kaiser Y, van der Toorn JE, Singh SS, et al. Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Eur Heart J 2022; 43: 3960-7.

4. Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.

5. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-46.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atorvastatin;Reactions Weekly;2024-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3